BioCentury
ARTICLE | Company News

Lundbeck snags PD play Prexton

March 23, 2018 5:35 PM UTC

H. Lundbeck A/S (CSE:LUN) will acquire Prexton Therapeutics B.V. (Oss, the Netherlands) for €100 million ($123.4 million) up front. Shareholders in the neurology company will also be eligible for up to €805 million ($993.2 million) in development, regulatory and sales milestones.

Lundbeck gains foliglurax (PXT002331), which is in a Phase II trial to reduce motor complications of levodopa therapy in Parkinson's disease patients. Data from the trial are expected in mid-2019. The candidate is a small molecule positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 4 (mGluR4; GRM4)...